NO20015972L - Screeningsmetoder for å endre dögnrytmeproteiner - Google Patents

Screeningsmetoder for å endre dögnrytmeproteiner

Info

Publication number
NO20015972L
NO20015972L NO20015972A NO20015972A NO20015972L NO 20015972 L NO20015972 L NO 20015972L NO 20015972 A NO20015972 A NO 20015972A NO 20015972 A NO20015972 A NO 20015972A NO 20015972 L NO20015972 L NO 20015972L
Authority
NO
Norway
Prior art keywords
alter
ability
directed
screening methods
phosphorylation
Prior art date
Application number
NO20015972A
Other languages
English (en)
Other versions
NO20015972D0 (no
NO330241B1 (no
Inventor
George Keesler
Cesare Mondadori
Zhengbin Yao
Fernando Camacho
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20015972D0 publication Critical patent/NO20015972D0/no
Publication of NO20015972L publication Critical patent/NO20015972L/no
Publication of NO330241B1 publication Critical patent/NO330241B1/no

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Peptides Or Proteins (AREA)
NO20015972A 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1) NO330241B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774599A 1999-06-08 1999-06-08
PCT/US2000/015633 WO2000075669A1 (en) 1999-06-08 2000-06-07 Screening methods for altering circadian rhythm proteins

Publications (3)

Publication Number Publication Date
NO20015972D0 NO20015972D0 (no) 2001-12-06
NO20015972L true NO20015972L (no) 2002-02-05
NO330241B1 NO330241B1 (no) 2011-03-14

Family

ID=23277866

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20015972A NO330241B1 (no) 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1)
NO20100431A NO20100431L (no) 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)
NO20100430A NO20100430L (no) 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20100431A NO20100431L (no) 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)
NO20100430A NO20100430L (no) 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr

Country Status (15)

Country Link
US (1) US6555328B1 (no)
EP (1) EP1183541B1 (no)
JP (1) JP4583682B2 (no)
KR (1) KR100722176B1 (no)
AT (1) ATE322016T1 (no)
AU (1) AU767800B2 (no)
BR (1) BR0011437A (no)
CA (1) CA2375450C (no)
DE (1) DE60026998T2 (no)
IL (2) IL146729A0 (no)
MX (1) MXPA01011417A (no)
NO (3) NO330241B1 (no)
NZ (1) NZ514603A (no)
WO (1) WO2000075669A1 (no)
ZA (1) ZA200108962B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476188B1 (en) 1998-06-19 2002-11-05 The Rockefeller University Clock gene and methods of use thereof
US6436628B1 (en) 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
KR100722176B1 (ko) * 1999-06-08 2007-05-29 아벤티스 파마슈티칼스 인크. 일주기 리듬 단백질을 변화시키기 위한 스크리닝 방법
US7659387B1 (en) * 1999-11-18 2010-02-09 University Of Virginia Transgenic mammals introduced a Period 1 promoter that confers rhythmical expression
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU2002248338A1 (en) * 2001-01-11 2002-07-24 University Of Utah Research Foundation Identification of an advanced sleep phase syndrome gene in humans
AU2003278333A1 (en) * 2002-10-25 2004-05-13 University Of Surrey Polymorphism in the per3 gene as a indicator in the diagnosis and treatment of circadian rhythm sleep disorders
AU2003293150A1 (en) * 2002-11-27 2004-06-23 University Of Utah Research Foundation Casein kinase i epsilon and casein kinase i delta and sleep in humans
AU2005277460A1 (en) * 2004-08-19 2006-03-02 Aventis Pharmaceuticals Inc. 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I epsilon
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
JO2724B1 (en) 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
US20100028871A1 (en) * 2006-05-31 2010-02-04 National Institute Of Radiological Sciences Light-inducible and rhythmically expressed genes and method for screening substances that affect an internal clock system
JP5518479B2 (ja) * 2006-10-25 2014-06-11 ザ ロックフェラー ユニヴァーシティ Aβ関連障害の処置のための方法およびその組成物
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
WO2015054819A1 (en) * 2013-10-14 2015-04-23 Nanjing University Method for identifying advanced feeding rhythm syndrome and application thereof
KR101600144B1 (ko) * 2013-12-20 2016-03-04 서울대학교산학협력단 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법
RU2016132574A (ru) 2014-01-09 2018-02-12 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2017083835A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York Inhibition of tor complex 2 increases immunity against bacterial infection
WO2023129377A1 (en) * 2022-01-03 2023-07-06 The Johns Hopkins University Methods and materials for treating heart attack

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157137A (ja) * 1997-08-28 1999-03-02 Sanyo Bussan Kk 遊技機用特別図柄表示装置
KR100246893B1 (ko) * 1997-12-29 2000-05-01 윤종용 전자렌지용 도어
AU3976099A (en) * 1998-05-07 1999-11-23 President & Fellows Of Harvard College, The Compositions and methods involving regulation of mammalian circadian rhythms
KR100722176B1 (ko) * 1999-06-08 2007-05-29 아벤티스 파마슈티칼스 인크. 일주기 리듬 단백질을 변화시키기 위한 스크리닝 방법

Also Published As

Publication number Publication date
DE60026998T2 (de) 2007-04-05
NO20100430L (no) 2002-02-05
CA2375450A1 (en) 2000-12-14
NO20015972D0 (no) 2001-12-06
KR20020033101A (ko) 2002-05-04
ZA200108962B (en) 2003-01-30
EP1183541B1 (en) 2006-03-29
MXPA01011417A (es) 2002-06-04
EP1183541A1 (en) 2002-03-06
NO330241B1 (no) 2011-03-14
CA2375450C (en) 2009-04-28
AU5468900A (en) 2000-12-28
JP4583682B2 (ja) 2010-11-17
KR100722176B1 (ko) 2007-05-29
NO20100431L (no) 2002-02-05
BR0011437A (pt) 2002-03-05
IL146729A (en) 2007-06-17
US6555328B1 (en) 2003-04-29
WO2000075669A1 (en) 2000-12-14
DE60026998D1 (de) 2006-05-18
ATE322016T1 (de) 2006-04-15
JP2003501074A (ja) 2003-01-14
AU767800B2 (en) 2003-11-27
NZ514603A (en) 2003-10-31
IL146729A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
NO20100431L (no) Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
EA200001244A1 (ru) Комбинационная терапия для лечения биполярных расстройств
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
EA199700280A1 (ru) Ингибиторы протеинкиназы с
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
EA200200625A1 (ru) Антипикорнавирусные соединения и композиции, их фармацевтическое применение и вещества для их синтеза
PT948604E (pt) Produtos e metodos relacionados com pyk2
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
DE3854209D1 (de) Analyse von organischen Substanzen.
EA200500603A1 (ru) ПРОИЗВОДНЫЕ [6,7-ДИГИДРО-5H-ИМИДАЗО[1,2-α]ИМИДАЗОЛ-3-СУЛЬФОНИЛАМИНО]ПРОПИОНАМИДА
ATE73995T1 (de) Verwendung von penicillamin zur behandlung von immunmangelkrankheiten.
DE69606837D1 (de) Gerät zur Überprüfung der Bestimmungen von klinischen Analysen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees